(Total Views: 238)
Posted On: 02/12/2018 6:45:54 PM
Post# of 72446
Re: Loose Lips #41912
Well it wasn't in clinical trials at the time of the deal. It's $50M upfront, part of which has to go toward phase 1 costs. Then, if it makes it into phase 2B they get another $125M. If they opt to move forward after a successful phase 2B they will pay out another $200M. J&J isn't putting up $1B for a preclinical drug, they're putting up $50M with payment structures in place as it advances.
Also keep in mind this is an oral drug for Crohn's. That's quite a bit more fashionable than a retention enema for Ulcerative Proctitis. Very different animals as far a valuation goes. If we developed an oral delivery form that treats Crohn's or UC, then we would have earned the $50M and would be on the cusp of claiming $125M to start a phase 2B.
Go IPIX!
Also keep in mind this is an oral drug for Crohn's. That's quite a bit more fashionable than a retention enema for Ulcerative Proctitis. Very different animals as far a valuation goes. If we developed an oral delivery form that treats Crohn's or UC, then we would have earned the $50M and would be on the cusp of claiming $125M to start a phase 2B.
Go IPIX!
(0)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
